A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
2 de junio de 2026 actualizado por: Takeda
A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Mezagitamab (TAK-079) in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure. AMR happens when the kidney recipient's immune system makes antibodies that attack the donor kidney. Antibodies are proteins made by the immune system to recognize foreign cells. Over time, this attack can damage kidney tissue and cause the transplant to fail. Because AMR can be serious, there is a need for treatments that are safe, work well, and are supported by good evidence.
The main aim of this study is to find out how safe mezagitamab is and how well adults with AMR tolerate it compared with placebo. A placebo looks like medicine but has no active ingredients. The study will also look at whether mezagitamab helps to control inflammation in the transplanted kidney and helps keep kidney function stable, compared with placebo.
Participants will be placed by chance in 1 of the 3 treatment groups in equal numbers. Two groups will receive mezagitamab in two different doses. One group will receive placebo. This means that out of every 3 participants, 2 will receive mezagitamab and 1 will receive placebo.
During the study, participants will visit their study clinic several times.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Estimado)
36
Fase
- Fase 2
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Takeda Contact
- Número de teléfono: +1-877-825-3327
- Correo electrónico: medinfoUS@takeda.com
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Descripción
Key inclusion criteria:
- The participant aged 18 to 80 years.
- The participant must have a biopsy-confirmed diagnosis of active or chronic active late AMR (defined as greater than [>] 6 month after kidney transplant) without concurrent definitive TCMR (Grade 1a and above) as defined by the 2022 Banff classification.
- Biopsy within 30 days prior to screening, or performed during screening period within protocol-defined window.
- If the participant has received treatment for rejection, then the repeat biopsy and donor specific antibody (DSA) testing must have been performed at least 6 weeks after stopping the treatment.
- The participant with either human leukocyte antigen (HLA) class I and/or II DSA.
- eGFR > 30 milliliters per minute per 1.73 square meters (mL/min/1.73m^2).
Key exclusion criteria:
- The participant has blood type A, B, AB, or O (ABO) incompatible transplant.
- The participant has a history of multiple organ transplants, including en bloc and dual kidney transplants.
- Participant likely to require renal replacement therapy within the subsequent 30 days.
- Participants who have received an anti-cluster of differentiation 38 (CD38) therapy in the last 1 year or have past history of failing to achieve AMR resolution despite treatment with an anti-CD38 therapy.
The participant has received any previous treatment with other immunosuppressant or immunomodulatory therapy:
a) Within 6 months of signing the informed consent form (ICF) as listed below:
- Complement system inhibitors (such as, eculizumab).
- Proteasome inhibitors (such as, bortezomib).
- Interleukin-6 (IL-6)/IL-6R antibody (such as, tocilizumab).
- Anti-cluster of differentiation 20 (CD20) antibody (such as, rituximab). b) Within 6 weeks of signing the ICF as listed below:
- Intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) or plasmapheresis
- The participant has active infection with hepatitis B virus, hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- Participant with serious infection within 2 weeks or with opportunistic infection within 2 months prior to signing ICF. Participant with active or untreated tuberculosis, or those with high suspicion of tuberculosis are also excluded.
- History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ.
Key Note: Other protocol specified inclusion and exclusion criteria apply.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm A: Mezagitamab + Placebo
Participants will receive mezagitamab up to Week 24, followed by placebo up to Week 48, followed by an observation period up to Week 70.
|
Mezagitamab subcutaneous (SC) injection.
Otros nombres:
Mezagitamab-matching placebo SC injection.
|
|
Experimental: Arm B: Mezagitamab
Participants will receive mezagitamab up to Week 48, followed by an observation period up to Week 70.
|
Mezagitamab subcutaneous (SC) injection.
Otros nombres:
|
|
Comparador activo: Arm C: Placebo
Participants will receive placebo up to Week 48, followed by an observation period up to Week 70.
|
Mezagitamab-matching placebo SC injection.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Arms A, B, and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Periodo de tiempo: Up to Week 70
|
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the trial intervention, whether or not the occurrence is considered related to the trial intervention.
An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the trial intervention.
TEAEs are defined as AEs with start dates at the time of or following the first exposure to investigational medicinal product (IMP).
|
Up to Week 70
|
|
Arms A, B, and C: Number of Participants With Related TEAEs
Periodo de tiempo: Up to Week 70
|
A related AE is an AE that is considered related to the IMP.
Related TEAEs are defined as related AEs with start dates at the time of or following the first exposure to IMP.
|
Up to Week 70
|
|
Arms A, B, and C: Number of Participants With Serious Adverse Events (SAEs)
Periodo de tiempo: Up to Week 70
|
An SAE is any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.
|
Up to Week 70
|
|
Arms A, B, and C: Number of Participants With AEs of Special Interest
Periodo de tiempo: Up to Week 70
|
AEs of special interest are AEs that are considered specific to the IMP.
|
Up to Week 70
|
|
Arms A, B, and C: Number of Participants With AE Leading to Treatment Discontinuation
Periodo de tiempo: Up to Week 70
|
Up to Week 70
|
|
|
Arms A, B, and C: Number of Participants With Clinically Significant Abnormal Laboratory Test Results and Vital Signs
Periodo de tiempo: Up to Week 70
|
Up to Week 70
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Arms A, B, and C: Percentage of Participants With Achievement of Biopsy-Proven Histologic Resolution of AMR Activity at Weeks 24 and 48
Periodo de tiempo: Weeks 24 and 48
|
Achievement of biopsy-proven histological resolution of AMR activity will be assessed by the 2022 Banff classification criteria.
The Banff 2022 Classification provides a standardized framework for evaluating kidney transplant biopsies using lesion scoring.
|
Weeks 24 and 48
|
|
Arms A, B, and C: Microvascular Inflammation (MVI) Score in Biopsy Samples at Weeks 24 and 48
Periodo de tiempo: Weeks 24 and 48
|
MVI is an important marker of allograft loss and is defined as the sum of glomerulitis and peritubular capillaritis scores (g+ptc) on kidney histology.
|
Weeks 24 and 48
|
|
Arms A, B, and C: Percentage of Participants Who Achieve a MVI Score of 0 at Weeks 24 and 48
Periodo de tiempo: Weeks 24 and 48
|
Weeks 24 and 48
|
|
|
Arms A, B, and C: Change From Baseline in MVI score at Weeks 24 and 48
Periodo de tiempo: Baseline, Weeks 24 and 48
|
Baseline, Weeks 24 and 48
|
|
|
Arms A, B, and C: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Weeks 24, 48 and 70
Periodo de tiempo: Baseline, Weeks 24, 48 and 70
|
eGFR is a measure of kidney function calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
|
Baseline, Weeks 24, 48 and 70
|
|
Arms A, B, and C: Change From Baseline in Donor-Derived Cell-Free DNA (dd-cfDNA) at Weeks 24, 48 and 70
Periodo de tiempo: Baseline, Weeks 24, 48 and 70
|
dd-cfDNA are DNA fragments released from injured donor cells.
It serves as a noninvasive, quantitative method that reflects allograft injury and is associated with AMR activity in kidney transplant recipients.
|
Baseline, Weeks 24, 48 and 70
|
|
Arms A, B, and C: Change From Baseline in Urine Protein Creatinine Ratio (UPCR) at Weeks 24, 48 and 70
Periodo de tiempo: Baseline, Weeks 24, 48 and 70
|
UPCR is a measure of protein excretion calculated from a urine sample, as the ratio of urine protein to creatinine, and used to assess kidney function.
|
Baseline, Weeks 24, 48 and 70
|
|
Arm B: Percentage of Participants With Achievement of Biopsy-Proven Histologic Resolution of AMR Activity at Week 70
Periodo de tiempo: Week 70
|
Week 70
|
|
|
Arm B: MVI Score in Biopsy Samples at Week 70
Periodo de tiempo: Week 70
|
Week 70
|
|
|
Arm B: Percentage of Participants Who Achieve a MVI Score of 0 at Week 70
Periodo de tiempo: Week 70
|
Week 70
|
|
|
Arm B: Change From Baseline in MVI score at Week 70
Periodo de tiempo: Week 70
|
Week 70
|
|
|
Arms A, B, and C: Percentage of Participants With T-Cell Mediated Rejection (TCMR) by Biopsy at Weeks 24 and 48
Periodo de tiempo: Weeks 24 and 48
|
Weeks 24 and 48
|
|
|
Arm B: Percentage of Participants With TCMR by Biopsy at Week 70
Periodo de tiempo: Week 70
|
Week 70
|
|
|
Arms A and B: Serum Concentration of Mezagitamab
Periodo de tiempo: Pre-dose and at multiple time points post-dose up to Week 70
|
Pre-dose and at multiple time points post-dose up to Week 70
|
|
|
Arms A, B and C: Number of Participants With Anti-Drug Antibody
Periodo de tiempo: Pre-dose and at multiple time points post-dose up to Week 70
|
Pre-dose and at multiple time points post-dose up to Week 70
|
|
|
Arms A, B and C: Number of Participants With Neutralizing Antibody
Periodo de tiempo: Pre-dose and at multiple time points post-dose up to Week 70
|
Pre-dose and at multiple time points post-dose up to Week 70
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Director de estudio: Study Director, Takeda
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Enlaces Útiles
- Click here to ask Takeda's chatbot for comprehensive and easy-to-understand information about clinical trials - even across products and indications - in your local language.
- Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
1 de septiembre de 2026
Finalización primaria (Estimado)
15 de enero de 2029
Finalización del estudio (Estimado)
15 de enero de 2029
Fechas de registro del estudio
Enviado por primera vez
22 de mayo de 2026
Primero enviado que cumplió con los criterios de control de calidad
22 de mayo de 2026
Publicado por primera vez (Actual)
29 de mayo de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
4 de junio de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
2 de junio de 2026
Última verificación
1 de junio de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- TAK-079-2002
- 2026-526239-20-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
SÍ
Descripción del plan IPD
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5).
These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Criterios de acceso compartido de IPD
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/.
For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Sí
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
producto fabricado y exportado desde los EE. UU.
Sí
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Mezagitamab
-
TakedaTerminadoMiastenia gravisEstados Unidos, España, Canadá, Serbia, Italia, Polonia
-
TakedaReclutamientoPúrpura trombocitopénica inmune (PTI)Japón, Estados Unidos, Australia, Porcelana, España, Italia, Reino Unido, Bulgaria, Hong Kong, Croacia, Corea del Sur, Turquía (Türkiye), Países Bajos, Polonia
-
TakedaReclutamientoPúrpura trombocitopénica inmune (PTI)Estados Unidos, Japón, Australia, Porcelana, España, Italia, Reino Unido, Bulgaria, Hong Kong, Croacia, Corea del Sur, Turquía (Türkiye), Francia, Países Bajos, Polonia, Grecia
-
TakedaTerminadoGlomerulonefritis | Enfermedad del riñonTaiwán, Australia, Hungría, España, Reino Unido, Porcelana, Estados Unidos, Japón, Singapur, Corea del Sur, Italia
-
TakedaTerminadoMieloma múltiple en recaída y/o refractario (RRMM)Estados Unidos, Canadá
-
TakedaReclutamientoEnfermedad del riñonPorcelana, Estados Unidos, Suiza, Taiwán, Japón, España, Francia, Eslovenia, Singapur, Italia, Reino Unido, Países Bajos, Malasia, Australia, Noruega, Argentina, Alemania, Corea del Sur, Polonia, Hong Kong, Austria, Suecia, Canadá, Turquía... y más
-
Millennium Pharmaceuticals, Inc.Terminado
-
TakedaTerminado